276 related articles for article (PubMed ID: 27405747)
1. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Kasamatsu T; Saitoh T; Ino R; Gotoh N; Mitsui T; Shimizu H; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Murakami H
Hematol Oncol; 2017 Dec; 35(4):711-718. PubMed ID: 27405747
[TBL] [Abstract][Full Text] [Related]
2. IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma.
Kasamatsu T; Kimoto M; Takahashi N; Minato Y; Gotoh N; Takizawa M; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Saitoh T; Murakami H
Hematol Oncol; 2018 Feb; 36(1):196-201. PubMed ID: 28786198
[TBL] [Abstract][Full Text] [Related]
3. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Vangsted AJ; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Nexø BA; Vogel U
Ann Hematol; 2011 Oct; 90(10):1173-81. PubMed ID: 21347685
[TBL] [Abstract][Full Text] [Related]
4. IL-10RB rs2834167 (A/G) polymorphism is associated with the susceptibility to systemic lupus erythematosus: evidence from a study in Chinese Han population.
Peng H; Liu CY; Zhou M; Wen PF; Zhang M; Qiu LJ; Ni J; Liang Y; Pan HF; Ye DQ
Inflammation; 2013 Dec; 36(6):1218-24. PubMed ID: 23749100
[TBL] [Abstract][Full Text] [Related]
5. CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.
Qin XY; Lu J; Li GX; Wen L; Liu Y; Xu LP; Chang YJ; Liu KY; Jiang ZF; Huang XJ
Ann Hematol; 2018 Mar; 97(3):485-495. PubMed ID: 29264740
[TBL] [Abstract][Full Text] [Related]
6. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.
Du J; Yuan Z; Zhang C; Fu W; Jiang H; Chen B; Hou J
Leuk Res; 2010 Nov; 34(11):1453-8. PubMed ID: 20122728
[TBL] [Abstract][Full Text] [Related]
7. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
Vangsted AJ; Søeby K; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Vogel U; Werge T; Rasmussen HB
BMC Cancer; 2010 Aug; 10():404. PubMed ID: 20684753
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of IL-10 affect the severity and prognosis of myelodysplastic syndrome.
Kasamatsu T; Saitoh T; Minato Y; Shimizu H; Yokohama A; Tsukamoto N; Handa H; Sakura T; Murakami H
Eur J Haematol; 2016 Mar; 96(3):245-51. PubMed ID: 25941112
[TBL] [Abstract][Full Text] [Related]
9. Association of a
Venugopal G; O'Regan NL; Babu S; Schumann RR; Srikantam A; Merle R; Hartmann S; Steinfelder S
Am J Trop Med Hyg; 2019 Feb; 100(2):344-350. PubMed ID: 30594267
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
[TBL] [Abstract][Full Text] [Related]
11. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.
Du J; Huo J; Shi J; Yuan Z; Zhang C; Fu W; Jiang H; Yi Q; Hou J
Haematologica; 2011 May; 96(5):729-37. PubMed ID: 21228035
[TBL] [Abstract][Full Text] [Related]
13. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).
Terragna C; Remondini D; Martello M; Zamagni E; Pantani L; Patriarca F; Pezzi A; Levi G; Offidani M; Proserpio I; De Sabbata G; Tacchetti P; Cangialosi C; Ciambelli F; Viganò CV; Dico FA; Santacroce B; Borsi E; Brioli A; Marzocchi G; Castellani G; Martinelli G; Palumbo A; Cavo M
Oncotarget; 2016 Mar; 7(9):9666-79. PubMed ID: 26575327
[TBL] [Abstract][Full Text] [Related]
14. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Terpos E; Migkou M; Christoulas D; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Iakovaki M; Panagiotidis I; Ziogas DC; Fotiou D; Kastritis E; Dimopoulos MA
Blood Cancer J; 2016 May; 6(5):e428. PubMed ID: 27232930
[TBL] [Abstract][Full Text] [Related]
15. PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma.
Kasamatsu T; Awata M; Ishihara R; Murakami Y; Gotoh N; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Saitoh T; Murakami H
Clin Exp Med; 2020 Feb; 20(1):51-62. PubMed ID: 31620907
[TBL] [Abstract][Full Text] [Related]
16. TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
Bagratuni T; Terpos E; Eleutherakis-Papaiakovou E; Kalapanida D; Gavriatopoulou M; Migkou M; Liacos CI; Tasidou A; Matsouka C; Mparmparousi D; Dimopoulos MA; Kastritis E
Br J Haematol; 2016 Jan; 172(1):44-7. PubMed ID: 26564000
[TBL] [Abstract][Full Text] [Related]
17. CRP/IL-6/IL-10 Single-Nucleotide Polymorphisms Correlate with the Susceptibility and Severity of Community-Acquired Pneumonia.
Chou SC; Ko HW; Lin YC
Genet Test Mol Biomarkers; 2016 Dec; 20(12):732-740. PubMed ID: 27705004
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
